Literature DB >> 17414320

IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.

Mojgan Ahmadzadeh1, Paul A Antony, Steven A Rosenberg.   

Abstract

Although FOXP3 is primarily expressed by regulatory CD4 T cells (Treg) in vivo, polyclonal activation of human CD8 T cells can result in the expression of FOXP3 in a fraction of CD8 T cells. However, the cellular lineage and mechanism of FOXP3 induction in CD8 T cells remain unclear. Here, we demonstrate that interleukin-2 (IL-2) induces FOXP3 expression in OKT3-stimulated or antigen-stimulated CD8 T cells, indicating that FOXP3 expression is neither limited to a unique subset of CD8 T cells nor dependent on the mode of T-cell receptor stimulation. In the absence of IL-2, antigen stimulation resulted in T-cell activation and acquisition of effector function without induction of FOXP3, indicating that acquisition of effector function is independent of induction of FOXP3 expression in CD8 T cells. Interestingly, IL-15, but not IL-7 or IL-21, also led to de novo induction of FOXP3 in antigen-specific CD8 T cells, suggesting that signaling by IL-2/IL-15Rbeta chain is pivotal for induction of FOXP3 in human CD8 T cells. These findings indicate that induction of FOXP3 is intrinsic to CD8 T cells that are activated in the presence of IL-2 or IL-15, and in vitro-induced expression of FOXP3 cannot be simply interpreted as an indicator of Treg activity or activation marker.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414320      PMCID: PMC2174606          DOI: 10.1097/CJI.0b013e3180336787

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  34 in total

1.  Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function.

Authors:  Angela M Thornton; Erin E Donovan; Ciriaco A Piccirillo; Ethan M Shevach
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

Review 2.  A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

Authors:  Jason D Fontenot; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

3.  Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells.

Authors:  Estelle Bettelli; Maryam Dastrange; Mohamed Oukka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-24       Impact factor: 11.205

4.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

5.  TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.

Authors:  Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

6.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Luke M Williams; James L Dooley; Andrew G Farr; Alexander Y Rudensky
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

7.  Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans.

Authors:  Mary E Morgan; Jolanda H M van Bilsen; Aleida M Bakker; Bianca Heemskerk; Marco W Schilham; Franca C Hartgers; Berendina G Elferink; Linda van der Zanden; René R P de Vries; Tom W J Huizinga; Tom H M Ottenhoff; René E M Toes
Journal:  Hum Immunol       Date:  2005-01       Impact factor: 2.850

8.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

9.  Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia.

Authors:  Claudia R Ruprecht; Marco Gattorno; Francesca Ferlito; Andrea Gregorio; Alberto Martini; Antonio Lanzavecchia; Federica Sallusto
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

10.  Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.

Authors:  Ruka Setoguchi; Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  14 in total

1.  Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity.

Authors:  Mojgan Ahmadzadeh; Anna Pasetto; Li Jia; Drew C Deniger; Sanja Stevanović; Paul F Robbins; Steven A Rosenberg
Journal:  Sci Immunol       Date:  2019-01-11

2.  Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

Authors:  Xin Yao; Mojgan Ahmadzadeh; Yong-Chen Lu; David J Liewehr; Mark E Dudley; Fang Liu; David S Schrump; Seth M Steinberg; Steven A Rosenberg; Paul F Robbins
Journal:  Blood       Date:  2012-05-03       Impact factor: 22.113

3.  Safety and immunologic effects of IL-15 administration in nonhuman primates.

Authors:  Carolina Berger; Michael Berger; Robert C Hackman; Michael Gough; Carole Elliott; Michael C Jensen; Stanley R Riddell
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

4.  A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells.

Authors:  Aixin Yu; Linjian Zhu; Norman H Altman; Thomas R Malek
Journal:  Immunity       Date:  2009-01-29       Impact factor: 31.745

5.  FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

Authors:  Mojgan Ahmadzadeh; Aloisio Felipe-Silva; Bianca Heemskerk; Daniel J Powell; John R Wunderlich; Maria J Merino; Steven A Rosenberg
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

6.  Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Authors:  Nicolas Montcuquet; Patricia Mercier-Letondal; Sylvain Perruche; Anne Duperrier; Mélanie Couturier; Abdelghani Bouchekioua; Mark Bonyhadi; Christophe Ferrand; Pierre Tiberghien; Eric Robinet
Journal:  Immunology       Date:  2008-04-26       Impact factor: 7.397

7.  Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.

Authors:  Paria Mirmonsef; Gladys Tan; Gang Zhou; Tricia Morino; Kimberly Noonan; Ivan Borrello; Hyam I Levitsky
Journal:  Blood       Date:  2007-12-06       Impact factor: 22.113

Review 8.  Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Authors:  Ulf Petrausch; Christian H Poehlein; Shawn M Jensen; Chris Twitty; James A Thompson; Ilka Assmann; Sachin Puri; Michael G LaCelle; Tarsem Moudgil; Levi Maston; Kevin Friedman; Sarah Church; Elisa Cardenas; Daniel P Haley; Edwin B Walker; Emmanuel Akporiaye; Andrew D Weinberg; Sidney Rosenheim; Todd S Crocenzi; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Bernard A Fox
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

9.  Negative feedback regulation of T cells via interleukin-2 and FOXP3 reciprocity.

Authors:  Zoran Popmihajlov; Kendall A Smith
Journal:  PLoS One       Date:  2008-02-13       Impact factor: 3.240

10.  Foxp3 expression in human cancer cells.

Authors:  Vaios Karanikas; Matthaios Speletas; Maria Zamanakou; Fani Kalala; Gedeon Loules; Theodora Kerenidi; Angeliki K Barda; Konstantinos I Gourgoulianis; Anastasios E Germenis
Journal:  J Transl Med       Date:  2008-04-22       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.